Aldeyra's Reproxalap has Experts Mixed on Seasonal Allergic Conjunctivitis Focus in Phase III
BioPharmaceutical
Report



- Mar 19, 2019
Eisai's Lenvima for First-line HCC Is Approvable but Noninferiority Data to SOC May Slow Uptake


- Mar 12, 2019
Immunomedics’ Sacituzumab Has Insufficient Dataset to Pursue Accelerated Approval


- Mar 12, 2019
Shooting for the Universe


- Mar 12, 2019
Biosimilar Uptake Still Plagued by Interchangeability Hurdles


- Mar 12, 2019
Alnylam vs Dicerna Trade Secret Litigation May Be Influenced by Emotive Arguments


- Mar 12, 2019
BeiGene’s Phase III BGB-3111 in WMHas Unclear Efficacy Advantage Over Imbruvica


- Mar 12, 2019
Corbus’ Phase II Anabasum in Dermatomyositis Garners Mixed Expert Expectations


- Mar 12, 2019
Strategic Shift of Dong-A ST Co. Ltd. in Drug Discovery


- Mar 12, 2019
Medical Device: Growing Cybersecurity Threat and Need for More Regulation


- Mar 12, 2019
Eisai’s Lenvima Should See FDA Approval in Hepatocellular Carcinoma (HCC)


- Mar 12, 2019
Western CAR-Ts face Chinese Development Hurdles Due to Regulatory Uncertainty


- Mar 12, 2019
Legislation to Force Payer Coverage of AbuseDeterrent Opioids Faces Resistance


- Mar 12, 2019
Roche’s GALLIUM Results Draw Skepticism about Changing Practice in First-Line Follicular Lymphoma


- Mar 12, 2019
Humira Biosimilar Unlikely to Reach the Market Before 2020